Because chondrosarcomas vary widely in their behavior, and because anticipating their behavior based on histology alone can be challenging, genetic markers represent an appealing area of inquiry that may help us refine our prognostic approaches. Isocitrate dehydrogenase (IDH) mutations are involved in the pathogenesis of a variety of neoplasms, and recently, IDH1/2 mutations have been found in the tissue of benign cartilage tumors as well as in conventional chondrosarcomas and highly aggressive dedifferentiated chondrosarcomas. However, their association with patient survival is still controversial.

中文翻译：

---

IDH1 R132 突变是否与骨软骨肉瘤患者的不良预后相关？


由于软骨肉瘤的行为差异很大，并且仅根据组织学预测其行为可能具有挑战性，因此遗传标记代表了一个有吸引力的研究领域，可以帮助我们完善预后方法。异柠檬酸脱氢酶（IDH）突变参与多种肿瘤的发病机制，最近在良性软骨肿瘤组织以及传统软骨肉瘤和高度侵袭性去分化软骨肉瘤组织中发现了IDH1/2突变。然而，它们与患者生存的关系仍然存在争议。